Mukka Proteins acquires 51% stake in FABBCO, strengthens BSF technology and bio-protein capabilities
The acquisition of a 51% stake in FABBCO, coupled with comprehensive operational agreements for BSF technology, technical assistance, and supply of BSF eggs, represents a significant strategic move for Mukka Proteins. This is expected to have a substantial impact on the company's future growth, technological advancement, and competitive position in the bio-protein sector.
Mukka Proteins is acquiring a majority 51% stake in FABBCO, a company specializing in Bio Cycle and Bio Protein Technology, which strategically expands its capabilities in Black Soldier Fly (BSF) technology and secures essential supply and technical expertise for its projects. This indicates growth and vertical integration.
* Mukka Proteins Limited (MUKKA) has entered into a Shareholders Agreement (SHA) and a Share Purchase Agreement (SPA) on 2 September 2025. * The agreements are with FABBCO Bio Cycle and Bio Protein Technology Private Limited (FABBCO) and its existing shareholders for the subscription/acquisition of equity shares in FABBCO. * Mukka Proteins will acquire a 51% stake in the paid-up equity share capital of FABBCO. * The company will subscribe to 2,436 equity shares and acquire 2,422 equity shares from existing shareholders, each with a face value of ₹1,000 and a premium of ₹11,250. * Key terms of the agreement include: * FABBCO will utilize the proceeds to clear existing debts and redeem outstanding preference shares. * All Black Soldier Fly (BSF) technology projects, unless expressly excluded, will operate under FABBCO's brand. * FABBCO will provide full-spectrum technical assistance to Mukka Proteins' BSF project in Bangalore. * FABBCO will receive an operational support fee of ₹0.50 (fifty paise) for every kilogram of waste processed at Mukka Proteins' BSF facilities in Bangalore. * FABBCO will supply BSF eggs to Mukka Proteins’ facilities in Mangalore and Bangalore. * The Board of Directors of FABBCO will be reconstituted to comprise an equal number of directors nominated by Mukka Proteins and the existing shareholders. * Certain "Reserved matters" for FABBCO require Mukka Proteins' prior written consent. * The parties involved are not related to the promoter/promoter group, and the transaction is not considered a related party transaction.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under mergers & acquisitions. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.